Combination therapy for relapsed or refractory angioimmunoblastic T-cell lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of five drugs (tislelizumab, cyclophosphamide, mitoxantrone liposomes, chidamide, and prednisone) for patients with angioimmunoblastic T-cell lymphoma (AITL) that has come back or not responded to previous treatment. The goal is to see if this combination can shrink tumors or stop the disease from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with AITL (a type of blood cancer) and have at least one tumor that can be measured on a scan.
- Your cancer must have come back or not gotten better after at least one prior treatment (like chemotherapy or stem cell transplant).
- You must be at least 18 years old and have a good enough performance status to be up and about (ECOG score 0-3).
- Your doctor expects you to live at least 3 more months.
- You must not have had certain previous treatments like mitoxantrone, PD-1/PD-L1 inhibitors, or histone deacetylase inhibitors (like chidamide) for AITL.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of five drugs for people newly diagnosed with a rare type of lymphoma called angioimmunoblastic T-cell lymphoma (AITL). The goal is to see if this treatment helps control the cancer.
This trial tests a new combination of drugs (azacytidine plus CAOLD) for people with a specific type of T-cell lymphoma called AITL that has come back or not responded to previous treatment. The goal is to see if this treatment can work better than current options.
This trial tests two drugs, azacitidine and abatacept, given together for T-cell lymphoma that has come back or not improved after earlier treatment. The goal is to see if this combination can control the cancer better, potentially offering a new option for patients.
This trial is testing a combination of two drugs for T-cell lymphoma that has returned after prior treatment. The drugs are belinostat (given as an infusion) plus either azacitidine or pralatrexate. The goal is to see if this combination can help control the lymphoma and for how long.
This trial tests a combination of three drugs (mitoxantrone liposome, cytarabine, and venetoclax) for people with AML that has returned or not responded to treatment. The goal is to see if this combination can help control the leukemia.
This trial tests a combination of three targeted drugs (zanubrutinib, rituximab, lenalidomide) plus an immunotherapy drug (tislelizumab) for people with follicular lymphoma that has returned or not responded to at least two prior treatments. The goal is to see if this combination is safe and effective.
Hear when a new Angioimmunoblastic T-Cell Lymphoma Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.